[Federal Register Volume 75, Number 240 (Wednesday, December 15, 2010)]
[Notices]
[Page 78259]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-31426]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-D-0616]
Draft Guidance for Industry on Codevelopment of Two or More
Unmarketed Investigational Drugs for Use in Combination; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft guidance for industry entitled ``Codevelopment
of Two or More Unmarketed Investigational Drugs for Use in
Combination.'' This guidance is intended to assist sponsors in the
codevelopment of two or more novel (not previously marketed) drugs to
be used in combination to treat a disease or condition. This guidance
provides recommendations and advice on how to address certain
scientific and regulatory issues that will arise during codevelopment.
The guidance is not intended to apply to development of fixed-dose
combinations of already marketed drugs or to development of a single
new investigational drug to be used in combination with an approved
drug or drugs. The guidance is also not intended to apply to vaccines,
gene or cellular therapies, blood products, or medical devices.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by February 14, 2011.
ADDRESSES: Submit written requests for single copies of the draft
guidance to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Colleen Locicero, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm 4216, Silver Spring, MD 20993-0002, 301-
796-1114.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance for industry
entitled ``Codevelopment of Two or More Unmarketed Investigational
Drugs for Use in Combination.'' The guidance is intended to assist
sponsors interested in developing two or more novel (not previously
marketed) drugs to be used in combination. Recent scientific advances
have increased our understanding of the pathophysiological processes
that underlie many complex diseases, such as cancer, cardiovascular
disease, and infectious diseases. This increased understanding has
provided further impetus for new therapeutic approaches that rely
primarily or exclusively on combinations of drugs directed at multiple
therapeutic targets to improve treatment response and minimize
development of resistance. In settings in which combination therapy
provides significant therapeutic advantages, there is growing interest
in the development of combinations of investigational drugs not
previously developed for any purpose.
Because the existing developmental and regulatory paradigm focuses
primarily on assessment of the effectiveness and safety of a single new
investigational drug acting alone, or in combination with an approved
drug, FDA believes guidance is needed to assist sponsors in the
codevelopment of two or more unmarketed drugs. This guidance is
intended to describe a high-level, generally applicable approach to
codevelopment of two or more unmarketed drugs. It describes the
criteria for determining when codevelopment is an appropriate option,
makes recommendations about nonclinical and clinical development
strategies, and addresses certain regulatory process issues. The
guidance does not apply to vaccines, gene or cellular therapies, or
blood products.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on companion
diagnostic devices. It does not create or confer any rights for or on
any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of the applicable statutes and regulations.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet may obtain the document at
either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.
Dated: December 9, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-31426 Filed 12-14-10; 8:45 am]
BILLING CODE 4160-01-P